JP2023518411A5 - - Google Patents
Info
- Publication number
- JP2023518411A5 JP2023518411A5 JP2022556035A JP2022556035A JP2023518411A5 JP 2023518411 A5 JP2023518411 A5 JP 2023518411A5 JP 2022556035 A JP2022556035 A JP 2022556035A JP 2022556035 A JP2022556035 A JP 2022556035A JP 2023518411 A5 JP2023518411 A5 JP 2023518411A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- group
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025188453A JP2026021531A (ja) | 2020-03-18 | 2025-11-07 | 神経刺激性ステロイド及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991234P | 2020-03-18 | 2020-03-18 | |
| US62/991,234 | 2020-03-18 | ||
| PCT/US2021/022933 WO2021188778A2 (en) | 2020-03-18 | 2021-03-18 | Neuroactive steroids and their methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025188453A Division JP2026021531A (ja) | 2020-03-18 | 2025-11-07 | 神経刺激性ステロイド及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518411A JP2023518411A (ja) | 2023-05-01 |
| JP2023518411A5 true JP2023518411A5 (https=) | 2024-03-29 |
| JP7817179B2 JP7817179B2 (ja) | 2026-02-18 |
Family
ID=75478218
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556035A Active JP7817179B2 (ja) | 2020-03-18 | 2021-03-18 | 神経刺激性ステロイド及びその使用方法 |
| JP2025188453A Pending JP2026021531A (ja) | 2020-03-18 | 2025-11-07 | 神経刺激性ステロイド及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025188453A Pending JP2026021531A (ja) | 2020-03-18 | 2025-11-07 | 神経刺激性ステロイド及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240239835A9 (https=) |
| EP (1) | EP4121438A2 (https=) |
| JP (2) | JP7817179B2 (https=) |
| CN (1) | CN115551874A (https=) |
| AR (1) | AR121609A1 (https=) |
| AU (1) | AU2021238346A1 (https=) |
| CA (1) | CA3175324A1 (https=) |
| IL (1) | IL296371A (https=) |
| TW (1) | TW202143976A (https=) |
| WO (1) | WO2021188778A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| TW201930269A (zh) | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| EP4321519B1 (en) | 2018-10-12 | 2026-04-08 | Sage Therapeutics, LLC | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| JP2025538551A (ja) * | 2022-11-21 | 2025-11-28 | セージ セラピューティクス， エルエルシー | 負のｎｍｄａ調節化合物及びその使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DE69435286D1 (de) * | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| NZ298567A (en) * | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| ATE284895T1 (de) * | 1995-06-06 | 2005-01-15 | Euro Celtique Sa | Neuroaktive steroide der androstan- und pregnanreihe |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| CA2848212C (en) * | 2011-09-08 | 2022-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| KR20250174100A (ko) * | 2018-12-05 | 2025-12-11 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| CN113272315B (zh) * | 2018-12-26 | 2023-08-08 | 张家口华健致远生物科技有限公司 | 一类类固醇化合物及其用途 |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CN112391512B (zh) * | 2019-08-13 | 2022-03-18 | 宝山钢铁股份有限公司 | 一种高磁感取向硅钢及其制造方法 |
| IL294606A (en) | 2020-01-12 | 2022-09-01 | Brii Biosciences Inc | Neuroactive steroids and a pharmaceutical preparation containing them |
| JP2024074633A (ja) * | 2022-11-21 | 2024-05-31 | 小松ウオール工業株式会社 | 間仕切り装置と、間仕切り装置における横桟の支持構造 |
-
2021
- 2021-03-18 WO PCT/US2021/022933 patent/WO2021188778A2/en not_active Ceased
- 2021-03-18 IL IL296371A patent/IL296371A/en unknown
- 2021-03-18 JP JP2022556035A patent/JP7817179B2/ja active Active
- 2021-03-18 TW TW110109815A patent/TW202143976A/zh unknown
- 2021-03-18 US US17/912,301 patent/US20240239835A9/en active Pending
- 2021-03-18 CN CN202180034459.1A patent/CN115551874A/zh active Pending
- 2021-03-18 AR ARP210100680A patent/AR121609A1/es unknown
- 2021-03-18 CA CA3175324A patent/CA3175324A1/en active Pending
- 2021-03-18 AU AU2021238346A patent/AU2021238346A1/en active Pending
- 2021-03-18 EP EP21718329.2A patent/EP4121438A2/en active Pending
-
2025
- 2025-11-07 JP JP2025188453A patent/JP2026021531A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518411A5 (https=) | ||
| JP2022510683A5 (https=) | ||
| JP2017531020A5 (https=) | ||
| JP2023500328A5 (https=) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2019520417A5 (https=) | ||
| RU2016151727A (ru) | Нейроактивные стероиды, композиции и их применения | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2023537632A5 (https=) | ||
| JP2022548696A5 (https=) | ||
| JP2022534424A5 (https=) | ||
| WO2018013597A4 (en) | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors | |
| JP2024543512A5 (https=) | ||
| JP2018502891A5 (https=) | ||
| JP2022504607A5 (https=) | ||
| JP2018505898A5 (https=) | ||
| RU2005139398A (ru) | Циклические сульфонамиды для ингибирования гамма-секретазы | |
| IL256433A (en) | Cot modulators and methods for using them | |
| JP2005514398A5 (https=) | ||
| JP2021510695A5 (https=) | ||
| AU2017254523A1 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2003531103A5 (https=) | ||
| JP2025501762A5 (https=) | ||
| CA2334189A1 (en) | Bridged indenopyrrolocarbazoles |